March 2 (Reuters) – Medical products maker Smith & Nephew forecast its 2026 trading profit to grow around 8% organically, with revenue leverage and cost cuts offsetting pressures from inventory revaluation, tariffs, and a challenging Chinese market.
The British company finished a three‑year turnaround that revamped its orthopaedic division, cut costs, and lifted growth in its wound management and sports medicine units, following margin pressures from inflation and supply‑chain disruptions.
Smith & Nephew also plans to further simplify its portfolio and reduce inventory by around $500 million under a new strategy, it said in December, while investing in higher-growth areas such as sports medicine.
The company, which makes orthopaedic implants, wound dressings, and other surgical aids, reported a trading profit of $1.21 billion for the year ended December 2025, up 15.5% year-on-year, and in line with market expectations.
(Reporting by Yamini Kalia in Bengaluru; Editing by Rashmi Aich)
